Scientific Publications

Cubała et al. (2026) GH001 vs Placebo in Patients With Treatment-Resistant Depression

JAMA Psychiatry

• Read

Reckweg et al. (2025). Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT

Frontiers in Psychology

• Read

Reckweg et al. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression

Frontiers in Psychiatry

• Read

Reckweg et al. (2021). A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5- Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers

Frontiers in Pharmacology

• Read

Poster: Rapid Antidepressant Effects of Inhaled GH001 in Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized, Controlled Trial with 6-Month Follow-Up

• View Poster

Poster: Suicidal Ideation and Behavior in Patients with Treatment-Resistant Depression Treated with GH001

• View Poster

Poster: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode

• View Poster

Poster: Safety and Tolerability Results From a Phase 2b, Double-Blind Trial With an Open-Label Extension of GH001 in Treatment-Resistant Depression

• View Poster

Poster: Psychoactive Effects of GH001 in Patients With Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomised Controlled Trial

• View Poster

Poster: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Bipolar II Disorder and a Current Major Depressive Episode

• View Poster

Poster: Results of a Phase 1 Clinical Trial (GH001-HV-103) to Determine the Safety and Tolerability of Mebufotenin (5-MeO-DMT), Administered via Inhalation (GH001) in Healthy Subjects

• View Poster

Poster: Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized Controlled Trial

• View Poster

Poster: Safety and Tolerability of GH001 in Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomized, Controlled Trial

• View Poster

Poster: Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients With Postpartum Depression

• View Poster

Poster: Results from Early-Stage Trials of Inhaled Mebufotenin (GH001) in Healthy Volunteers and Patients with Treatment-Resistant Depression

• View Poster

Poster (P.0411): Determination of inhibition constants for three psychedelic drugs for 5-HT 1A and 5-HT 2A receptors in postmortem human brain

• View Poster

Poster (M231): Results of a Phase 1 Clinical Trial to Determine the Safety and Tolerability of GH002 (Intravenous Mebufotenin) in Healthy Volunteers

• View Poster